体外受精中的临床辅助治疗:不断增长的清单
综述指出,体外受精(IVF)治疗中不断增多的临床辅助治疗(如生长激素、阿司匹林、肝素、脱氢表雄酮、睾酮、男女抗氧化剂及宫腔镜筛查)多在缺乏明确获益证据的情况下仓促进入常规实践,增加治疗复杂性和总体费用。当前综述未发现高质量证据支持这些辅助治疗用于常规实践,需开展大规模、设计良好的随机试验评估其有效性和安全性,并亟需建立基于证据的新干预引入机制。
要点
- 多数IVF辅助治疗缺乏明确获益证据却仓促进入常规实践。
- 辅助治疗增加IVF复杂性和总体费用,由夫妇和医疗提供方承担。
- 需大规模随机试验评估辅助治疗的有效性和安全性。
核心结论
- 当前综述未发现高质量证据支持这些IVF辅助治疗用于常规实践,需开展大规模、设计良好的随机试验评估其有效性和安全性。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 多数IVF辅助治疗(如生长激素、阿司匹林、肝素、脱氢表雄酮、睾酮、男女抗氧化剂及宫腔镜筛查)在缺乏明确获益证据的情况下被仓促引入常规临床实践。
关键数值与推荐
- 当前综述未发现高质量证据支持这些IVF辅助治疗用于常规实践。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A growing list of clinical adjuncts are being used during in vitro fertilization (IVF) treatment. Most of these IVF add-ons (such as growth hormone, aspirin, heparin, dehydroepiandrostenedione, testosterone, male and female antioxidants, and screening hysteroscopy) are being introduced into routine clinical practice in a hurried manner without any clear evidence of benefit in most cases. These add-ons make the IVF more complicated and increase the overall cost for the treatment, which is borne by the couples and health care providers. Our current review found no high-quality evidence to support the use of these IVF add-ons in routine practice. Large, well-designed, randomized trials must be conducted to evaluate the effectiveness and safety of these interventions. There is also a pressing need to develop an evidence-dictated mechanism for introducing newer interventions into routine clinical settings.
引用
- Kamath MS, Mascarenhas M, Franik S, et al. Clinical adjuncts in in vitro fertilization: a growing list. Fertil Steril. 2019. PMID: 31703943. doi:10.1016/j.fertnstert.2019.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。